1. Familial thrombotic microangiopathy in a child with coenzyme Q10 deficiency-associated glomerulopathy.
- Author
-
Lin KY, Lam CW, Chan EY, Lee M, Chung BH, Fung CW, Rodenburg R, Licht C, and Lap-Tak Ma A
- Subjects
- Humans, Male, Mitochondrial Diseases genetics, Mitochondrial Diseases complications, Mitochondrial Diseases diagnosis, Muscle Spasticity genetics, Muscle Spasticity etiology, Infant, Muscle Weakness etiology, Muscle Weakness genetics, Nephrotic Syndrome genetics, Nephrotic Syndrome complications, Nephrotic Syndrome etiology, Plasma Exchange, Antibodies, Monoclonal, Humanized therapeutic use, Child, Preschool, Ataxia, Ubiquinone analogs & derivatives, Ubiquinone therapeutic use, Ubiquinone deficiency, Thrombotic Microangiopathies genetics, Thrombotic Microangiopathies etiology, Thrombotic Microangiopathies diagnosis, Thrombotic Microangiopathies therapy
- Abstract
We report a child with biallelic COQ6 variants presenting with familial thrombotic microangiopathy (TMA). A Chinese boy presented with steroid-resistant nephrotic syndrome at 8 months old and went into kidney failure requiring peritoneal dialysis at 15 months old. He presented with hypertensive encephalopathy with the triad of microangiopathic haemolytic anaemia, thrombocytopenia, and acute on chronic kidney injury at 25 months old following a viral illness. Kidney biopsy showed features of chronic TMA. He was managed with supportive therapy and plasma exchanges and maintained on eculizumab. However, he had another TMA relapse despite complement inhibition a year later. Eculizumab was withdrawn, and supportive therapies, including ubiquinol (50 mg/kg/day) and vitamins, were optimized. He remained relapse-free since then for 4 years. Of note, his elder sister succumbed to multiple organ failure with histological evidence of chronic TMA at the age of 4. Retrospective genetic analysis revealed the same compound heterozygous variants in the COQ6 gene., Competing Interests: Declarations. Consent to participate: The authors declare that they have obtained consent from the patient discussed in the report. Conflict of interest: All the authors declared no competing interests., (© 2024. The Author(s), under exclusive licence to International Pediatric Nephrology Association.)
- Published
- 2025
- Full Text
- View/download PDF